Radiolabeled ligands targeting prostate-specific membrane antigen (PSMA) are currently being established. Prostate-specific membrane antigen radioligand therapy with 177Lu-PSMA-617 is a promising treatment in metastasized castration-resistant prostate cancer with high efficacy and safety and seems to prolong progression-free survival and overall survival. We present 68Ga-PSMA PET/CT images during and after 2 therapy courses, including each 4 cycles of 177Lu-PSMA-617, and prostate-specific antigen–level history of a 77-year-old heavily pretreated patient with metastasized castration-resistant prostate cancer.
From the Departments of *Nuclear Medicine and
†Urology, University Hospital Münster, Münster, Germany.
Received for publication May 26, 2018; revision accepted June 10, 2018.
Conflicts of interest and sources of funding: The University of Münster received consulting fees from ABXGmbH, Radeberg, Germany, for K.R. and M.B. W.R. is funded by a research grant of the Medical Faculty of the University of Münster. None declared to A.B. and M.W.
Correspondence to: Wolfgang Roll, MD, Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, Building A1, 48149 Münster, Germany. E-mail: Wolfgang.Roll@ukmuenster.de.